Trials / Terminated
TerminatedNCT02452528
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARC-520 | |
| DRUG | Placebo | |
| DRUG | Entecavir | 0.5 or 1.0 mg/day orally |
| DRUG | Tenofovir | 300 mg/day orally |
| DRUG | diphenhydramine | 50 mg orally as pretreatment antihistamine |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2015-05-22
- Last updated
- 2025-11-03
- Results posted
- 2017-11-01
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02452528. Inclusion in this directory is not an endorsement.